Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Development of small bisquaternary cholinesterase inhibitors as drugs for pre-treatment of nerve agent poisonings

K. Kuca, JZ. Karasova, O. Soukup, J. Kassa, E. Novotna, V. Sepsova, A. Horova, J. Pejchal, M. Hrabinova, E. Vodakova, D. Jun, E. Nepovimova, M. Valis, K. Musilek,

. 2018 ; 12 (-) : 505-512. [pub] 20180309

Language English Country New Zealand

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18033228

Background: Intoxication by nerve agents could be prevented by using small acetylcholinesterase inhibitors (eg, pyridostigmine) for potentially exposed personnel. However, the serious side effects of currently used drugs led to research of novel potent molecules for prophylaxis of organophosphorus intoxication. Methods: The molecular design, molecular docking, chemical synthesis, in vitro methods (enzyme inhibition, cytotoxicity, and nicotinic receptors modulation), and in vivo methods (acute toxicity and prophylactic effect) were used to study bispyridinium, bisquinolinium, bisisoquinolinium, and pyridinium-quinolinium/isoquinolinium molecules presented in this study. Results: The studied molecules showed non-competitive inhibitory ability towards human acetylcholinesterase in vitro that was further confirmed by molecular modelling studies. Several compounds were selected for further studies. First, their cytotoxicity, nicotinic receptors modulation, and acute toxicity (lethal dose for 50% of laboratory animals [LD50]; mice and rats) were tested to evaluate their safety with promising results. Furthermore, their blood levels were measured to select the appropriate time for prophylactic administration. Finally, the protective ratio of selected compounds against soman-induced toxicity was determined when selected compounds were found similarly potent or only slightly better to standard pyridostigmine. Conclusion: The presented small bisquaternary molecules did not show overall benefit in prophylaxis of soman-induced in vivo toxicity.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033228
003      
CZ-PrNML
005      
20181026101728.0
007      
ta
008      
181008s2018 nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/DDDT.S133038 $2 doi
035    __
$a (PubMed)29563775
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Kuca, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove. Biomedical Research Center, University Hospital Hradec Kralove.
245    10
$a Development of small bisquaternary cholinesterase inhibitors as drugs for pre-treatment of nerve agent poisonings / $c K. Kuca, JZ. Karasova, O. Soukup, J. Kassa, E. Novotna, V. Sepsova, A. Horova, J. Pejchal, M. Hrabinova, E. Vodakova, D. Jun, E. Nepovimova, M. Valis, K. Musilek,
520    9_
$a Background: Intoxication by nerve agents could be prevented by using small acetylcholinesterase inhibitors (eg, pyridostigmine) for potentially exposed personnel. However, the serious side effects of currently used drugs led to research of novel potent molecules for prophylaxis of organophosphorus intoxication. Methods: The molecular design, molecular docking, chemical synthesis, in vitro methods (enzyme inhibition, cytotoxicity, and nicotinic receptors modulation), and in vivo methods (acute toxicity and prophylactic effect) were used to study bispyridinium, bisquinolinium, bisisoquinolinium, and pyridinium-quinolinium/isoquinolinium molecules presented in this study. Results: The studied molecules showed non-competitive inhibitory ability towards human acetylcholinesterase in vitro that was further confirmed by molecular modelling studies. Several compounds were selected for further studies. First, their cytotoxicity, nicotinic receptors modulation, and acute toxicity (lethal dose for 50% of laboratory animals [LD50]; mice and rats) were tested to evaluate their safety with promising results. Furthermore, their blood levels were measured to select the appropriate time for prophylactic administration. Finally, the protective ratio of selected compounds against soman-induced toxicity was determined when selected compounds were found similarly potent or only slightly better to standard pyridostigmine. Conclusion: The presented small bisquaternary molecules did not show overall benefit in prophylaxis of soman-induced in vivo toxicity.
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    _2
$a buněčné linie $7 D002460
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a cholinesterasové inhibitory $x chemie $x farmakologie $7 D002800
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a HeLa buňky $7 D006367
650    _2
$a lidé $7 D006801
650    _2
$a molekulární modely $7 D008958
650    _2
$a molekulární struktura $7 D015394
650    _2
$a nervová bojová látka $x škodlivé účinky $7 D000067397
650    _2
$a knihovny malých molekul $x chemie $x farmakologie $7 D054852
650    _2
$a soman $x škodlivé účinky $7 D012999
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
700    1_
$a Karasova, Jana Zdarova $u Biomedical Research Center, University Hospital Hradec Kralove. Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence.
700    1_
$a Soukup, Ondrej $u Biomedical Research Center, University Hospital Hradec Kralove.
700    1_
$a Kassa, Jiri $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence.
700    1_
$a Novotna, Eva $u Biomedical Research Center, University Hospital Hradec Kralove.
700    1_
$a Sepsova, Vendula $u Biomedical Research Center, University Hospital Hradec Kralove. Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence.
700    1_
$a Horova, Anna $u Biomedical Research Center, University Hospital Hradec Kralove.
700    1_
$a Pejchal, Jaroslav $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence.
700    1_
$a Hrabinova, Martina $u Biomedical Research Center, University Hospital Hradec Kralove. Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence.
700    1_
$a Vodakova, Eva $u Biomedical Research Center, University Hospital Hradec Kralove.
700    1_
$a Jun, Daniel $u Biomedical Research Center, University Hospital Hradec Kralove. Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence.
700    1_
$a Nepovimova, Eugenie $u Department of Chemistry, Faculty of Science, University of Hradec Kralove. Biomedical Research Center, University Hospital Hradec Kralove.
700    1_
$a Valis, Martin $u Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Musilek, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove. Biomedical Research Center, University Hospital Hradec Kralove.
773    0_
$w MED00165856 $t Drug design, development and therapy $x 1177-8881 $g Roč. 12, č. - (2018), s. 505-512
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29563775 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181026102239 $b ABA008
999    __
$a ok $b bmc $g 1340854 $s 1030222
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 12 $c - $d 505-512 $e 20180309 $i 1177-8881 $m Drug design, development and therapy $n Drug des. dev. ther. $x MED00165856
LZP    __
$a Pubmed-20181008
Back

Find record

Citation metrics

Archiving options